These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 16231250)

  • 41. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
    Itani KM; Weigelt J; Li JZ; Duttagupta S
    Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Linezolid eradicates MRSA better than vancomycin from surgical-site infections.
    Weigelt J; Kaafarani HM; Itani KM; Swanson RN
    Am J Surg; 2004 Dec; 188(6):760-6. PubMed ID: 15619496
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
    Shorr AF; Kunkel MJ; Kollef M
    J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
    Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
    Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
    De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
    Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.
    Jang HC; Kim SH; Kim KH; Kim CJ; Lee S; Song KH; Jeon JH; Park WB; Kim HB; Park SW; Kim NJ; Kim EC; Oh MD; Choe KW
    Clin Infect Dis; 2009 Aug; 49(3):395-401. PubMed ID: 19569970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
    Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Linezolid in the treatment of Gram-positive prosthetic joint infections.
    Bassetti M; Vitale F; Melica G; Righi E; Di Biagio A; Molfetta L; Pipino F; Cruciani M; Bassetti D
    J Antimicrob Chemother; 2005 Mar; 55(3):387-90. PubMed ID: 15705640
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis.
    Stein GE; Schooley SL; Peloquin CA; Kak V; Havlichek DH; Citron DM; Tyrrell KL; Goldstein EJ
    Ann Pharmacother; 2005 Mar; 39(3):427-32. PubMed ID: 15701775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New treatment option for gram-positive infections in critically ill patients - overview over linezolid].
    Krueger WA; Unertl KE
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37(4):199-204. PubMed ID: 11967745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experience with linezolid therapy in children with osteoarticular infections.
    Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC
    Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
    Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA
    J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
    Martone WJ; Lamp KC
    Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study.
    Senneville E; Legout L; Valette M; Yazdanpanah Y; Giraud F; Beltrand E; Obert G; Dubreuil L; Migaud H; Mouton Y
    J Antimicrob Chemother; 2004 Oct; 54(4):798-802. PubMed ID: 15329363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
    Wilcox MH
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early experience with linezolid for infections in orthopaedics.
    Harwood PJ; Talbot C; Dimoutsos M; Sunderland G; Shaw D; Wilcox MH; Giannoudis PV
    Injury; 2006 Sep; 37(9):818-26. PubMed ID: 16620816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.